A recent clinical study found that a blood test measuring the protein p-tau217 can significantly improve the accuracy of Alzheimer's disease diagnosis, increasing it from 75.5% to 94.5%. The test also enhances clinicians' diagnostic confidence and can distinguish Alzheimer's from other conditions across all stages of cognitive decline. This blood test could provide a more accurate and less invasive way to diagnose Alzheimer's, potentially improving care for millions of people. The study followed 200 consecutive new patients aged 50 and older who presented with cognitive symptoms.